靶向调节性T细胞与成纤维细胞相互作用以增强脂肪性肝病相关肝细胞癌的免疫治疗
本研究采用单细胞转录组学、飞行时间流式细胞术和两个独立的空间转录组学平台,研究22例脂肪性肝病相关肝细胞癌(SLD-HCC)和31例非SLD-HCC的肿瘤微环境,并在103例独立队列、HCC模型及免疫治疗患者队列中验证。结果显示SLD-HCC存在冷免疫抑制微环境,TNFSF14-TNFRSF14介导的调节性T细胞与癌相关成纤维细胞相互作用是免疫治疗抵抗的关键驱动因素,阻断TNFRSF14可增强抗肿瘤免疫并与抗PD-1治疗产生协同效应。
要点
- SLD-HCC肿瘤微环境呈冷免疫抑制表型,CD8+ T细胞减少、调节性T细胞增加。
- 空间转录组学显示调节性T细胞与癌相关成纤维细胞在肿瘤边缘形成免疫抑制生态位。
- TNFSF14-TNFRSF14信号介导调节性T细胞与癌相关成纤维细胞相互作用,驱动免疫治疗抵抗。
核心结论
- SLD-HCC存在关键免疫和代谢适应,TNFSF14-TNFRSF14信号是免疫治疗抵抗的关键驱动因素。
- 靶向该信号轴可增强抗肿瘤免疫并提高免疫治疗疗效,为SLD-HCC提供有前景的治疗策略。
研究设计与样本
- 采用单细胞转录组学、飞行时间流式细胞术(CyTOF)和两个独立的空间转录组学平台研究22例SLD-HCC和31例非SLD-HCC的肿瘤微环境。
- 在103例独立患者队列中通过多重免疫组化验证,并在HCC模型和免疫治疗患者队列中评估临床相关性。
主要发现
- 免疫和脂质代谢通路发生显著改变,尤其涉及调节性T细胞(Tregs)和癌相关成纤维细胞(CAFs)。
- CyTOF显示冷免疫抑制微环境,CD8+ T细胞减少、Tregs增加。
- 空间转录组学显示Treg-CAF簇定位于肿瘤边缘,提示空间组织的免疫抑制生态位。
- TNFSF14-TNFRSF14介导的Treg-CAF相互作用被确定为SLD-HCC免疫治疗抵抗的关键驱动因素。
- 在高脂饮食HCC模型中阻断TNFRSF14可减少Tregs、增加活性CD8+和记忆CD4+ T细胞,并与抗PD-1治疗协同增强抗肿瘤免疫、克服免疫治疗抵抗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Steatotic liver disease-related hepatocellular carcinoma (SLD-HCC), a rising global challenge, is characterised by unique tumour microenvironment (TME) adaptations. OBJECTIVE: This study investigates the immune microenvironment and interactions driving immunosuppression and potential resistance to immunotherapy in SLD-HCC. DESIGN: We employed single-cell transcriptomics, cytometry by time-of-flight (CyTOF) and two independent spatial transcriptomics platforms to study the TME of 22 SLD-HCC and 31 non-SLD-HCC cases. Findings were further validated using multiplex immunohistochemistry in an independent cohort of 103 patients, an HCC model and an immunotherapy-treated patient cohort to evaluate clinical relevance. RESULTS: Our findings revealed significant alterations in immune and lipid metabolism pathways, particularly in regulatory T cells (Tregs) and cancer-associated fibroblasts (CAFs), suggesting distinct cellular adaptations to a high-fat TME and general immunosuppression. CyTOF revealed a cold, immunosuppressive TME with reduced CD8+ T cells and increased Tregs. Spatial transcriptomics further highlighted distinct Treg-CAF clusters localised at tumour margins, suggesting a spatially organised immunosuppressive niche. Mechanistically, tumour necrosis factor superfamily member 14 (TNFSF14)-tumour necrosis factor receptor superfamily member 14 (TNFRSF14)-mediated Treg-CAF interaction was identified as a critical driver of immunotherapy resistance in SLD-HCC. Blocking TNFRSF14 in an HCC model fed with a high-fat diet resulted in reduced Tregs, increased active CD8+ and memory CD4+ T cells, and a synergistic effect with anti-programmed cell death protein 1 therapy to enhance antitumour immunity and overcome immunotherapy resistance in SLD-HCC. CONCLUSION: This study uncovers critical immune and metabolic adaptations in SLD-HCC, identifying TNFSF14-TNFRSF14 signalling as a key driver of immunotherapy resistance. Targeting this signalling axis enhances antitumour immunity and improves immunotherapy efficacy, offering a promising therapeutic strategy for SLD-HCC.
引用
- Prawira A, Xu H, Mei Y, et al. Targeting Treg-fibroblast interaction to enhance immunotherapy in steatotic liver disease-related hepatocellular carcinoma. Gut. 2025. PMID: 40695620. doi:10.1136/gutjnl-2025-335084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。